Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group.

Vikelis M, Rikos D, Argyriou AA, Soldatos P, Tsironis C, Giakoumakis E, Xiromerisiou G, Chondrogianni M, Foska A, Koutsokera M, Notas K, Mavraki E, Dermitzakis EV, Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group

Open source

DOI: 10.3390/neurolint18040067
Published: 2026 Apr 1
Container: Neurology international
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/neurolint18040067,
  title = {Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group.},
  author = {Vikelis M and Rikos D and Argyriou AA and Soldatos P and Tsironis C and Giakoumakis E and Xiromerisiou G and Chondrogianni M and Foska A and Koutsokera M and Notas K and Mavraki E and Dermitzakis EV and Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group},
  year = {2026},
  journal = {Neurology international},
  doi = {10.3390/neurolint18040067},
  url = {https://doi.org/10.3390/neurolint18040067}
}

RIS

TY  - JOUR
TI  - Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group.
AU  - Vikelis M
AU  - Rikos D
AU  - Argyriou AA
AU  - Soldatos P
AU  - Tsironis C
AU  - Giakoumakis E
AU  - Xiromerisiou G
AU  - Chondrogianni M
AU  - Foska A
AU  - Koutsokera M
AU  - Notas K
AU  - Mavraki E
AU  - Dermitzakis EV
AU  - Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group
PY  - 2026
JO  - Neurology international
DO  - 10.3390/neurolint18040067
UR  - https://doi.org/10.3390/neurolint18040067
ER  -

APA

M, V., D, R., AA, A., P, S., C, T., E, G., G, X., M, C., A, F., M, K., K, N., E, M., EV, D., & Group, G. R. A. F. T. S. O. H. A. P. (. S. (2026). Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group.. Neurology international. https://doi.org/10.3390/neurolint18040067

Source records

pubmed · retrieved 2026-09-26T06:26:53.301Z